Abstract
Particulate structures hold great promise for the development of effective and affordable recombinant prophylactic as well as therapeutic vaccines. Different types of particulate structures, including virus-like particles (VLPs) and virosomes, have been developed depending on the nature of the viral pathogen to be targeted and the type of immune response (humoral vs cellular) to be elicited. Particulate structures allow the insertion or fusion of foreign antigenic sequences, resulting in chimeric particles delivering foreign antigens on their surface. Similarly, they are used as carriers for foreign antigens, including non-protein antigens, via chemical conjugation. Particulate structures, indeed, represent a very efficient system for delivering antigens to antigen presenting cells (APC) which, in turn, trigger and amplify the adaptive immune response. The present review will address the biological and immunological properties of particulate structures, in particular VLPs, as platform for vaccine development.
Keywords: Virus-like particles, vaccine, antigen-presenting cells, HIV, innate immunity, adaptive immunity
Current HIV Research
Title: Virus-Like Particles as Particulate Vaccines
Volume: 8 Issue: 4
Author(s): Luigi Buonaguro, Maria L. Tornesello and Franco M. Buonaguro
Affiliation:
Keywords: Virus-like particles, vaccine, antigen-presenting cells, HIV, innate immunity, adaptive immunity
Abstract: Particulate structures hold great promise for the development of effective and affordable recombinant prophylactic as well as therapeutic vaccines. Different types of particulate structures, including virus-like particles (VLPs) and virosomes, have been developed depending on the nature of the viral pathogen to be targeted and the type of immune response (humoral vs cellular) to be elicited. Particulate structures allow the insertion or fusion of foreign antigenic sequences, resulting in chimeric particles delivering foreign antigens on their surface. Similarly, they are used as carriers for foreign antigens, including non-protein antigens, via chemical conjugation. Particulate structures, indeed, represent a very efficient system for delivering antigens to antigen presenting cells (APC) which, in turn, trigger and amplify the adaptive immune response. The present review will address the biological and immunological properties of particulate structures, in particular VLPs, as platform for vaccine development.
Export Options
About this article
Cite this article as:
Buonaguro Luigi, L. Tornesello Maria and M. Buonaguro Franco, Virus-Like Particles as Particulate Vaccines, Current HIV Research 2010; 8 (4) . https://dx.doi.org/10.2174/157016210791208659
DOI https://dx.doi.org/10.2174/157016210791208659 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Multi-target Drug Designing for BTK, MMP9, Proteasome and TAK1 for the Clinical Treatment of Mantle Cell Lymphoma
Current Topics in Medicinal Chemistry Current Therapeutic Leads for the Treatment of Melanoma: Targeted Immunotherapy in the Post-genomic Era
Current Molecular Pharmacology Drug Delivery Systems and Combination Therapy by Using Vinca Alkaloids
Current Topics in Medicinal Chemistry Role of the Non-Receptor Tyrosine Kinase Fes in Cancer
Current Medicinal Chemistry Active-Targeted Nanotherapy Strategies for Prostate Cancer
Current Cancer Drug Targets TRAIL-Based Therapeutic Approaches for the Treatment of Pediatric Malignancies
Current Medicinal Chemistry The Ubiquitin-Proteasome System (UPS) and the Mechanism of Action of Bortezomib
Current Pharmaceutical Design Automated PET Radiotracer Manufacture on the BG75 System and Imaging Validation Studies of [18F]fluoromisonidazole ([18F]FMISO)
Current Radiopharmaceuticals Therapeutic Nucleic Acids
Recent Patents on Regenerative Medicine The Controlled Release of Drugs and Bioactive Compounds from Mesoporous Silica Nanoparticles
Current Drug Delivery Prodrugs in Photodynamic Anticancer Therapy
Current Pharmaceutical Design Structural and Mechanistic Insights of CRAC Channel as a Drug Target in Autoimmune Disorder
Current Drug Targets Hepatocyte Growth Factor Signaling in Cancer Metastasis
Current Signal Transduction Therapy Expression of Specificity Protein Transcription Factors in Pancreatic Cancer and their Association in Prognosis and Therapy
Current Medicinal Chemistry Inhibitors of Myostatin- and Proteasome-Dependent Signaling for Attenuating Muscle Wasting
Recent Patents on Regenerative Medicine Tumoral Drug Metabolism: Perspectives and Therapeutic Implications
Current Drug Metabolism Pathobiology and Prevention of Cancer Chemotherapy-Induced Bone Growth Arrest, Bone Loss, and Osteonecrosis
Current Molecular Medicine Neuropeptides as Autocrine Growth Factors in Cancer Cells
Current Pharmaceutical Design Minor-Groove Binding Agents: Rational Design of Carboxamide Bond Isosteres
Current Topics in Medicinal Chemistry Focal Adhesion Kinase as a Cancer Therapy Target
Anti-Cancer Agents in Medicinal Chemistry